These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30479671)

  • 1. Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper.
    Battisti NML; De Glas N; Sedrak MS; Loh KP; Liposits G; Soto-Perez-de-Celis E; Krok-Schoen JL; Menjak IB; Ring A
    Ther Adv Med Oncol; 2018; 10():1758835918809610. PubMed ID: 30479671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
    Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
    Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis.
    Guan Y; Shen G; Fang Q; Xin Y; Huo X; Li J; Zhao F; Ren D; Liu Z; Li Z; Zhao J
    Clin Exp Med; 2023 Jun; 23(2):245-254. PubMed ID: 35304677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting.
    Abdel-Razeq H; Sharaf B
    Drug Des Devel Ther; 2022; 16():727-735. PubMed ID: 35321498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care.
    Hui R; de Boer R; Lim E; Yeo B; Lynch J
    Asia Pac J Clin Oncol; 2021 Jan; 17 Suppl 1():3-14. PubMed ID: 33506626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials.
    Munzone E; Pagan E; Bagnardi V; Montagna E; Cancello G; Dellapasqua S; Iorfida M; Mazza M; Colleoni M
    ESMO Open; 2021 Dec; 6(6):100332. PubMed ID: 34864350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
    Sammons S; Shastry M; Dent S; Anders C; Hamilton E
    Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.
    Sammons S; Sedrak MS; Kimmick GG
    Drugs Aging; 2020 May; 37(5):331-348. PubMed ID: 32100240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
    BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.
    Dai Q; Wang Y; Liao M; Chen H
    Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and meta-analysis.
    Zhang M; Song J; Guo S; Jin F; Zheng A
    Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37283514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
    Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.
    Sharifi MN; Anandan A; Grogan P; O'Regan RM
    Cancer; 2020 Aug; 126(15):3400-3416. PubMed ID: 32426848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shifting Treatment Paradigms: Improvements in HR-Positive, HER-2- Negative Breast Cancer Care in Poland from a Clinical Perspective.
    Ziobro M; Grela-Wojewoda A
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis.
    Petrelli F; Dottorini L; Di Menna G; Borgonovo K; Parati MC; Rea CG; Ghilardi M; Ghidini A; Luciani A
    Breast; 2023 Oct; 71():138-142. PubMed ID: 37198053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
    Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
    Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study.
    Goyal RK; Chen H; Abughosh SM; Holmes HM; Candrilli SD; Johnson ML
    Cancer; 2023 Apr; 129(7):1051-1063. PubMed ID: 36760031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.
    Knudsen ES; Witkiewicz AK
    Oncotarget; 2016 Oct; 7(43):69111-69123. PubMed ID: 27564114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.